US FDA’s Biggest Post-COVID Challenge May Be Helped By Small Inspections Tweak In FDORA
Executive Summary
The omnibus spending bill included dozens of reform provisions related to the US FDA. One seemingly minor change to FDA’s inspection authorities could end up being a big help to the challenges ahead in catching up after the COVID-19 pandemic.
You may also be interested in...
Congress Wants Answers From US FDA On China And India Inspection Plans
House Republicans keep pressure on US FDA for plans to catch up on inspections after long COVID-19 hiatus. Recent cancer drug shortages could be a headline event to lead into larger probe.
Congress Wants Answers From US FDA On India And China Inspection Plans
House Republicans keep the pressure on the US FDA for plans to catch up on inspections after the long COVID-19 hiatus. Recent cancer drug shortages could be a headline event to lead into a larger probe.
US FDA Food Safety Overhaul Will Have Ripple Effects For Drug Inspections
A restructuring of FDA’s food safety operations includes changes to the agency-wide office that handles all inspections, including those of drug manufacturers. It’s another shift in the delicate balancing of centralized management of ORA with the specific needs and priorities of the different centers.